23andMe to Present at Upcoming Investor Conferences
February 22, 2023 16:05 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Reports FY2023 Third Quarter Financial Results
February 08, 2023 16:05 ET
|
23andMe Holding Co.
Third quarter revenue grew 18% to $67 million Consumer revenue grew 17% year over year FY2023 financial guidance raised to expected revenue range of $290 to $300 million SOUTH SAN FRANCISCO,...
23andMe to Report FY2023 Third Quarter Financial Results
January 26, 2023 16:05 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
December 01, 2022 12:00 ET
|
23andMe Holding Co.
-14 percent of those surveyed say they’re stressed, compared to more than 47 percent in 2020-Under 20 percent of those surveyed said COVID-19 would interfere with their traditional holiday plans; down...
23andMe Reports FY2023 Second Quarter Financial Results
November 07, 2022 16:01 ET
|
23andMe Holding Co.
Second quarter revenue grew 37% to $76 millionConsumer revenue grew 27% year over year due to the addition of telehealth revenueOn track to achieve FY2023 financial guidance SOUTH SAN FRANCISCO,...
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
November 07, 2022 08:00 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
October 27, 2022 06:45 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe to Report FY2023 Second Quarter Financial Results
October 24, 2022 16:05 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe to Present at Upcoming Investor Conferences
October 12, 2022 16:10 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
October 05, 2022 08:21 ET
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people...